CD300LG
CMRF35-like molecule 9
Also known as: CLM9, CLM9_HUMAN, Trem4
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q6UXG3
- Gene
- CD300LG
- Ensembl
- ENSG00000161649
- Chromosome
- 17
- Canonical length
- 332 aa
- Protein class
- CD markers, Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Calyx
OverviewNCBI Gene
Members of the CD300 (see MIM 606786)-like (CD300L) family, such as CD300LG, are widely expressed on hematopoietic cells. All CD300L proteins are type I cell surface glycoproteins that contain a single immunoglobulin (Ig) V-like domain (Takatsu et al., 2006 [PubMed 16876123]).[supplied by OMIM, Mar 2008]
Canonical amino-acid sequenceUniProt
332 residues, UniProt reviewed canonical sequence.
>Q6UXG3|CD300LG
1 MRLLVLLWGC LLLPGYEALE GPEEISGFEG DTVSLQCTYR EELRDHRKYW CRKGGILFSR
61 CSGTIYAEEE GQETMKGRVS IRDSRQELSL IVTLWNLTLQ DAGEYWCGVE KRGPDESLLI
121 SLFVFPGPCC PPSPSPTFQP LATTRLQPKA KAQQTQPPGL TSPGLYPAAT TAKQGKTGAE
181 APPLPGTSQY GHERTSQYTG TSPHPATSPP AGSSRPPMQL DSTSAEDTSP ALSSGSSKPR
241 VSIPMVRILA PVLVLLSLLS AAGLIAFCSH LLLWRKEAQQ ATETQRNEKF CLSRLTAEEK
301 EAPSQAPEGD VISMPPLHTS EEELGFSKFV SALocalizationUniProt · AlphaFold · HPA
Whether an antibody against CD300LG can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.54
- Highest tissue expression
- 124 nTPM
Expression across tissuesHPA
Tissue
- adipose tissue: 124 nTPM
- breast: 108 nTPM
- placenta: 55 nTPM
- tongue: 43 nTPM
- heart muscle: 38 nTPM
- skeletal muscle: 21 nTPM
Single-cell type
- vascular endothelial cells: 68 nCPM
- peritubular myoid cells: 29 nCPM
- cardiomyocytes: 22 nCPM
- sertoli cells: 18 nCPM
- leydig cells: 13 nCPM
- epididymal principal cells: 8.8 nCPM
Immune cell
- basophil: 0.5 nTPM
- myeloid DC: 0.3 nTPM
- neutrophil: 0.1 nTPM
- NK-cell: 0.1 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
Brain region
- midbrain: 1.1 nTPM
- basal ganglia: 1 nTPM
- cerebral cortex: 1 nTPM
- medulla oblongata: 1 nTPM
- amygdala: 0.9 nTPM
- cerebellum: 0.9 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.99
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.18
- DepMap mean gene effect
- -0.22
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CD300LG as an antibody target. Whether an autoantibody or antibody against CD300LG could matter depends on whether native CD300LG is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CD300LG is annotated at the cell surface, where native CD300LG is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label CD300LG as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...